For example, in cancers with KRAS-mutant—a key oncogenic driver found in colon, ovary, lung, and pancreas cancers—screening performed using CRISPR nuclease identified synthetic lethal dependencies whose loss cooperates with and sensitizes cancer cells to the inhibition of KRAS pathway effectors (Anderson et al., 2017). This evidence concerns the gene KRAS and cancer.